Medicare seniors get cheaper non-opioid pain drugs, no opioid gatekeeping
S. 3064 — Relief of Chronic Pain Act of 2025 · Filed by Steve Daines (R-MT) · 5 cosponsors · Introduced Oct 28, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill modifies Medicare Part D (prescription drug coverage) to make non-opioid chronic pain medications more affordable and accessible for seniors. Starting in 2026, qualifying non-opioid pain drugs would have no deductible, be placed on the lowest cost-sharing tier, and cannot be subject to step therapy (forcing patients to try opioids first) or prior authorization delays. The bill covers seven specific chronic pain conditions: diabetic neuropathy, endometriosis, fibromyalgia, musculoskeletal pain, neuropathic pain, post-herpetic neuralgia, and trigeminal neuralgia.
Why we flagged it
The bill's core function is to reduce out-of-pocket costs and administrative barriers for a specific class of medications under Medicare Part D. It is a targeted benefit expansion, not a broad policy reform.
What the text implies
- The bill defines 'qualifying' drugs by wholesale acquisition cost threshold, but the threshold value is not specified in the provided text ('as determined by Sec...' appears incomplete), creating potential ambiguity about which drugs actually qualify.
- By prohibiting step therapy that requires opioid use first, the bill may increase opioid-sparing prescribing patterns, which could reduce opioid-related adverse events but may also shift cost burden to insurers if non-opioid alternatives are more expensive.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers of non-opioid pain medications; specialty pharmaceutical companies; biologics manufacturers